Cardinal Health set to expand its nuclear pharmacy operation

Cardinal Health has revealed plans that will see it expand its nuclear pharmacy division through the setting up of three new radiopharmaceutical manufacturing sites.

The facilities will build positron emission topography (Pet) machines that enable medical experts to gain molecular images of relevant parts of a patient’s body and give them a better chance of making an accurate diagnosis.

It is anticipated that various research teams, clinics and hospitals will be keen to use the Pet technology, but it needs to be kept close to Cardinal Health’s own nuclear pharmacy sites because the agents that are used to identify diseases decompose within a matter of hours.

“Making Pet technology more accessible to a greater number of facilities, clinicians and patients is critical to the continued growth of molecular imaging,” said John Rademacher, general manager of specialty and nuclear pharmacy services for Cardinal Health.

Cardinal Health is a multi-billion pound business and it describes its aim as a company as being to make healthcare around the world “safer and more productive”.